Has Clovis Raymond received payments from drug or device companies?

Yes. Drug and device makers reported $7,012 in general payments to Clovis Raymond across 291 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Clovis Raymond did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Clovis Raymond come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Clovis Raymond

Psychiatry · Bardonia, NYNPI 1902034051

Payments from drug & device makers

$7,012in general payments, 2019–2025

Across 291 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$3K
Alkermes, Inc.$806
Johnson & Johnson$782
E.r. Squibb & Sons, L.L.C.$665
Otsuka America Pharmaceutical, Inc.$387
Lundbeck LLC$355
plus $1K from 15 others

What the payments were for

Food & beverage$6,90598%
Education$1072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	122	$2,600
Alkermes, Inc.	32	$806
Johnson & Johnson	21	$782
E.r. Squibb & Sons, L.L.C.	19	$665
Otsuka America Pharmaceutical, Inc.	14	$387
Lundbeck LLC	17	$355
Axsome Therapeutics, Inc.	9	$217
Adlon Therapeutics L.p.	13	$176
Ironshore Pharmaceuticals Inc.	7	$176
Supernus Pharmaceuticals, Inc.	8	$159
Neurocrine Biosciences, Inc.	6	$145
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	6	$133
Teva Pharmaceuticals USA, Inc.	3	$125
Collegium Pharmaceutical, Inc.	3	$71
Corium, LLC	2	$50
Idorsia Pharmaceuticals US Inc	2	$48
Luye Pharma (USA) Ltd.	2	$41
Indivior Inc.	2	$32
Orexo US, Inc.	1	$16
Tris Pharma Inc	1	$15
Sunovion Pharmaceuticals Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,012 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RexultiBrexpiprazole	17	$48,119
Invega SustennaPaliperidone Palmitate	12	$37,125
VraylarCariprazine Hcl	12	$23,856
LybalviOlanzapine/Samidorphan Malate	11	$16,846
VyvanseLisdexamfetamine Dimesylate	31	$13,988
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	58	$11,451
Aripiprazole	61	$6,125
Paliperidone ErPaliperidone	24	$3,762
Clonazepam	252	$2,367
Olanzapine	72	$1,979
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	57	$1,569
Quetiapine Fumarate	138	$1,568
Alprazolam	161	$1,324
Mirtazapine	81	$1,059
Trazodone Hcl	109	$967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti	$387	$48,11917 claims
Johnson & JohnsonInvega Sustenna	$782	$37,12512 claims
AbbVieVraylar	$2,600	$23,85612 claims
Alkermes, Inc.Lybalvi	$806	$16,84611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Bardonia

Elyssa BarronWhite Plains$12.8M
Mark DibuonoStaten Island$11.9M
Ronald BrennerHempstead$11.5M
Anton PorsteinssonRochester$7.6M
Michael LiebowitzNew York$7.1M
Leslie CitromePomona$5.7M
John KaneGlen Oaks$4M
Inna Yuryev-GolgerBrooklyn$3M
Subhdeep VirkBuffalo$3M
Paul EderNew York$2.7M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →